--- Connecting LPs & GPs worldwide
--- Connecting LPs & GPs worldwide
Biotech companies Inviragen and SingVax have merged their vaccine pipelines and their international product development capabilities to create a company that is developing vaccines for infectious diseases prevalent in emerging economies. Concurrently with the merger, the combined company has raised $15m in a series A equity investment from a syndicate of international venture capital investors, including Charter Life Sciences, Venture Investors, Bio*One Capital and Phillip Private Equity.
In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.
Become a Premium SubscriberIf you are already a AltAssets subscriber please log in below.
